Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00954915 · ClinicalTrials.gov registry record · Phase 1
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
A Phase 1 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00954915 is a Phase 1 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 1 participants.
The verdict
NCT00954915, a Phase 1 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis. The study will also evaluate how long teplizumab stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it improves psoriasis.
Interventions
- BIOLOGICAL teplizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-12 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00954915
The ClinicalTrials.gov registry entry for NCT00954915 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which teplizumab is the first listed.
NCT00954915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00954915 about?
NCT00954915 is a clinical study titled "Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis". The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis. The study will also evaluate how long teplizumab stays in the blood and how long it takes for it to leave the body, what is the highest dose th...
What is the current status of trial NCT00954915?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-12. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00954915?
The interventions under investigation include: teplizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00954915?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.